What panicky investors need to understand is that these companies will still generate revenue from COVID-19 vaccine shots. Over 400 people die from COVID-19 every day, so there's still a need and a demand for booster shots. Novavax stock isn't currently recommended, as BioNTech/Pfizer and Moderna have much greater market share – and emergency use authorizations (EUAs) from the U.S. government – for their Omicron BA.4/BA.5-adapted, single-booster-dose bivalent vaccines.